Skip to main content

Table 1 Patient baseline characteristics

From: Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre

 

DPYD variant N (%)

DPYD wildtype N (%)

Total N (%)

Total

33 (8.9)

337 (91.1)

370 (100)

Median age, years (range)

62 (30–88)

65 (28–90)

64 (28–90)

Sex

 Male

21 (63.6)

217 (64.4)

238 (64.3)

 Female

12 (37.4)

120 (35.6)

132 (35.7)

Tumour

 Colorectal

23 (69.7)

186 (55.2)

209 (56.5)

 Oesophagogastric

5 (15.2)

88 (26.1)

93 (25.1)

 Hepatopancreatic biliary

4 (12.1)

48 (14.2)

52 (14.1)

 Other a

1 (3.0)

15 (4.5)

16 (4.3)

Ethnicity

 White

27 (81.8)

247 (73.1)

274 (74.1)

 Asian

2 (6.1)

27 (8.0)

29 (7.8)

 Black

0 (0)

15 (4.4)

15 (4.1)

 Other

4 (12.1)

26 (7.7)

30 (8.1)

 Undisclosed

0 (0)

12 (3.6)

12 (3.2)

ECOG Performance Status

 0

10 (30.3)

90 (26.6)

100 (27.0)

 1

21 (63.6)

233 (68.9)

254 (68.6)

 2

2 (6.1)

14 (4.1)

16 (4.3)

  1. Abbreviations: DPYD – dihydropyrimidine dehydrogenase, ECOG – Eastern Co-operative Oncology Group. a includes ten patients with anal carcinoma, three patients with small bowel carcinoma, two patients with ampullary carcinoma and 1 patient with large cell neuroendocrine carcinoma